Evaluation of a new etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA

Journal of Clinical Microbiology

Volumn 46, Issue 9, 2008, Pages 3042-3047

  Yusof, Anne ^a   Engelhardt, Anette ^a   Karlsson, Åsa ^a   Bylund, Lina ^a   Vidh, Pamela ^a   Mills, Karen ^a   Wootton, Mandy ^b   Walsh, Timothy R ^b  

^a AB Biodisk Research Laboratories   (Sweden)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CELL LINEAGE; CULTURE MEDIUM; INOCULATION; METHODOLOGY; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; REAGENT STRIPS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

STAPHYLOCOCCUS AUREUS;

EID: 53649092490     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00265-08     Document Type: Article

References (31)

1. Anonymous. 2004. Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb. Mortal. Wkly. Rep. 53:322-323.
2. Anonymous. 2002. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:902.
3. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23.
4. Berger-Bachi, B. 2002. Resistance mechanisms of gram-positive bacteria. Int. J. Med. Microbiol. 292:27-35.
5. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
6. Cosgrove, S. E., K. C. Carroll, and T. M. Perl. 2004. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39:539-545.
7. Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
8. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, and F. C. Tenover. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439.
9. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
10. Hiramatsu, K., L. Cui, M. Kuroda, and T. Ito. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 9:486-493.
11. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
12. Howden, B. P. 2005. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern. Med. J. 35(Suppl. 2):S136-S140.
13. Howden, B. P., P. G. Charles, P. D. Johnson, P. B. Ward, and M. L. Grayson. 2005. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility? Antimicrob. Agents Chemother. 49:4816. (Author's reply, 49:4816-4817.)
14. Howden, B. P., P. D. Johnson, P. G. Charles, and M. L. Grayson. 2004. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 39:1544. (Author's reply, 39:1544-1545.)
15. Howden, B. P., P. B. Ward, P. D. Johnson, P. G. Charles, and M. L. Grayson. 2005. Low-level vancomycin resistance in Staphylococcus aureus - an Australian perspective. Eur. J. Clin. Microbiol. Infect. Dis. 24:100-108.
16. Howe, R. A., K. E. Bowker, T. R. Walsh, T. G. Feest, and A. P. MacGowan. 1998. Vancomycin-resistant Staphylococcus aureus. Lancet 351:602.
17. Howe, R. A., A. Monk, M. Wootton, T. R. Walsh, and M. C. Enright. 2004. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg. Infect. Dis. 10:855-857.
18. Howe, R. A., M. Wootton, T. R. Walsh, P. M. Bennett, and A. P. Macgowan. 2000. Heterogeneous resistance to vancomycin in Staphylococcus aureus. J. Antimicrob. Chemother. 45:130-132.
19. Pfeltz, R. F., and B. J. Wilkinson. 2004. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr. Drug Targets Infect. Disord. 4:273-294.
20. Tenover, F. C. 1999. Implications of vancomycin-resistant Staphylococcus aureus. J. Hosp. Infect. 43(Suppl.):S3-S7.
21. Tenover, F. C., J. W. Biddle, and M. V. Lancaster. 2001. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7:327-332.
22. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, S. K. McAllister, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
23. Tenover, F. C., and L. C. McDonald. 2005. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr. Opin. Infect. Dis. 18:300-305.
24. Tenover, F. C., M. J. Mohammed, J. Stelling, T. O'Brien, and R. Williams. 2001. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J. Clin. Microbiol. 39:241-250.
25. Turnidge, J., and M. L. Grayson. 1993. Optimum treatment of staphylococcal infections. Drugs 45:353-366.
26. Walsh, T. R., A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
27. Walsh, T. R., and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:657-675.
28. Wootton, M., P. M. Bennett, A. P. MacGowan, and T. R. Walsh. 2005. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains. J. Antimicrob. Chemother. 56:944-947.
29. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.
30. Wootton, M., A. P. Macgowan, and T. R. Walsh. 2005. Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and hetero-resistant GISA strains. Biochim. Biophys. Acta 1726:326-327.
31. Wootton, M., T. R. Walsh, and A. P. MacGowan. 2005. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3982-3983.